Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade
IDH mutation
elderly
geriatric assessment
high grade glioma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Nov 2022
09 Nov 2022
Historique:
received:
17
09
2022
revised:
27
10
2022
accepted:
03
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Background: Describe the characteristics, patterns of care, and predictive geriatric factors of elderly patients with IDHm high-grade glioma (HGG) included in the French POLA network. Material and Methods: The characteristics of elderly (≥70 years) patients IDHm HGG were compared to those of younger patients IDHm HGG (<70 years) and of elderly patients IDHwt HGG. Geriatric features were collected. Results: Out of 1433 HGG patients included, 119 (8.3%) were ≥70 years. Among them, 39 presented with IDHm HGG. The main characteristics of elderly IDHm HGG were different from those of elderly IDHwt HGG but similar to those of younger IDHm HGG. In contrast, their therapeutic management was different from those of younger IDHm HGG with less frequent gross total resection and radiotherapy. The median progression-free survival (PFS) and overall survival (OS) were longer for elderly patients IDHm HGG (29.3 months and 62.1 months) than elderly patients IDHwt HGG (8.3 months and 13.3 months) but shorter than those of younger patients IDHm HGG (69.1 months and not reached). Geriatric factors associated with PFS and OS were mobility, neuropsychological disorders, body mass index, and autonomy. Geriatric factors associated with PFS and OS were mobility, neuropsychological disorders, and body mass index, and autonomy. Conclusion: the outcome of IDHm HGG in elderly patients is better than that of IDHwt HGG. Geriatric assessment may be particularly important to optimally manage these patients.
Identifiants
pubmed: 36428602
pii: cancers14225509
doi: 10.3390/cancers14225509
pmc: PMC9688655
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Oncol. 2012 Aug;23(8):2166-2172
pubmed: 22250183
J Geriatr Oncol. 2019 Jan;10(1):159-163
pubmed: 30037767
Lancet. 2017 Oct 7;390(10103):1645-1653
pubmed: 28801186
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Neuro Oncol. 2014 Sep;16(9):1244-54
pubmed: 24723566
Ann Diagn Pathol. 2020 Dec;49:151653
pubmed: 33137656
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
J Neurooncol. 2020 Sep;149(3):421-427
pubmed: 32989681
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101
pubmed: 24782454
Cochrane Database Syst Rev. 2020 Mar 23;3:CD013261
pubmed: 32202316
J Clin Oncol. 2006 Jun 20;24(18):2715-22
pubmed: 16782911
Neurology. 2007 May 22;68(21):1831-6
pubmed: 17515545
Clin Neuropathol. 2014 Nov-Dec;33(6):399-406
pubmed: 25158679
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Oncologist. 2014 Dec;19(12):1258-67
pubmed: 25342314
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Cancer. 2016 Jan 15;122(2):189-97
pubmed: 26618888
Neurosurg Clin N Am. 2019 Jan;30(1):1-16
pubmed: 30470396
Ann Surg Oncol. 2011 Jan;18(1):239-45
pubmed: 20697823
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
PLoS One. 2014 Dec 11;9(12):e115060
pubmed: 25503576
Tumour Biol. 2013 Dec;34(6):3555-9
pubmed: 23904262
J Neurooncol. 2011 Jul;103(3):611-8
pubmed: 20953662
Neurology. 2010 Oct 26;75(17):1560-6
pubmed: 20975057
J Clin Oncol. 2012 Sep 1;30(25):3065-70
pubmed: 22851558
Drugs Aging. 2018 Aug;35(8):707-718
pubmed: 30039343
Curr Oncol Rep. 2017 Oct 26;19(12):81
pubmed: 29075865
Cancer Med. 2019 Jun;8(6):3286-3295
pubmed: 31016895
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31600898
J Geriatr Oncol. 2016 Nov;7(6):453-456
pubmed: 27478132
J Geriatr Oncol. 2019 Sep;10(5):770-778
pubmed: 31005645
N Engl J Med. 2007 Apr 12;356(15):1527-35
pubmed: 17429084
Neuro Oncol. 2015 Jun;17(6):868-81
pubmed: 25556920
Acta Neuropathol. 2010 Dec;120(6):707-18
pubmed: 21088844
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076